{
  "docId": "019de074-ddab-749d-b286-5e01e8bcb935",
  "docSlug": "f43e68719e672319f390e5844d5bc5fe",
  "documentTitle": "Chimerix | Investor Presentation Deck | 41 slides",
  "authorId": "chimerix",
  "authorName": "Chimerix",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 15,
  "pageCount": 41,
  "prevPage": 14,
  "nextPage": 16,
  "slideType": "comparison_table",
  "function": "compare_peers",
  "density": "dense",
  "nDataPoints": 35,
  "notes": "The table uses a color-coded heatmap (green/pink) to indicate positive vs negative characteristics of trial design and outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-ddab-749d-b286-5e01e8bcb935/15",
  "deckHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935",
  "deckJsonHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935.json",
  "deckAnchorHref": "/decks/019de074-ddab-749d-b286-5e01e8bcb935#slide-15",
  "components": [
    {
      "bbox": {
        "h": 0.07,
        "w": 0.76,
        "x": 0.21,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "WKA Yung, et al, British Journal Cancer, Aug 8, 2000; Teri Kreisl, et all, Journal Clinical Onocoloy,2009, Feb 10;27(5);740-5; Tracy Batchelor, et. all, Journal of Clinical Oncology, vol28, issue 17, Jun 10, 2010; David Reardon, et al, Clin Cancer Research Apr 2020; 26(7)1586-1594; Martin van den Bent, et al, Cancer Chemo & Pharma, 26 Oct 2017 80, 1209-1217; Yazmin Odia, et al, Journal Neuro-Oncology 127, 127-125 (2016)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d14da1b6-29cc-41ef-854b-93017fe12310",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.19,
        "x": 0.08,
        "y": 0.87
      },
      "kind": "legend",
      "text": "Positive Neutral Negative Characteristics",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9125f0f-f6d9-42f2-a96a-00297a1f717f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.94,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "table",
      "text": "Comparison table of ONC201 vs Temodal, Avastin, Cediranib, Rindopepimut, Depatuxizumab mafodotin, and Enzastaurin across 8 metrics.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d11f345e-6d2c-4b7a-98eb-f73ae9fd9f5d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.94,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Strong rationale for phase 3 success relative to recent GBM trials",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dab83950-85ad-4497-b12f-5d3c24bec529",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Comparison frame",
      "slug": "comparison-frame",
      "agent": null,
      "layer": "slide",
      "matchId": "504f9158-1fb2-4d9b-9202-b56d1a77a3c1",
      "evidence": "table/data: Comparison table of ONC201 vs Temodal, Avastin, Cediranib, Rindopepimut, Depatuxizumab mafodotin, and Enzastaurin across 8 metrics.",
      "confidence": 0.7
    },
    {
      "name": "NxN matrix",
      "slug": "matrix-nxn",
      "agent": null,
      "layer": "slide",
      "matchId": "6706bda1-d964-401f-aac9-113af01f00f6",
      "evidence": "table/data: Comparison table of ONC201 vs Temodal, Avastin, Cediranib, Rindopepimut, Depatuxizumab mafodotin, and Enzastaurin across 8 metrics.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison_table",
      "slug": null,
      "matchId": "58930a41-b8e1-403b-ad2f-12209c9836d3",
      "evidence": "Structured grid comparing multiple entities across common attributes.",
      "confidence": 1
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}